-
Mashup Score: 2Quizartinib, decitabine, and venetoclax combination therapy in patients with AML and prior exposure to FLT3 inhibitors. - 2 year(s) ago
During the European Hematology Association (EHA) 2022 Congress, the triplet combination of quizartinib, a FLT3 inhibitor, with decitabine and venetoclax in patients with FLT3-ITD-mutated acute myeloid leukemia (AML) was evaluated.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1The current standard of care for patients with lower-risk MDS - 2 year(s) ago
Shuh Ying Tan, MBBS, BMedSci, FRACP, FRCPA, St Vincent’s Hospital Melbourne, Melbourne, Australia, briefly discusses the current standard of care…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Shuh Ying Tan (@StVincentsMelb) discusses current standard of care treatment approaches for patients with lower-risk MDS: 🎥: https://t.co/4y69fcKDry @EHA_Hematology #EHA2022 #HemOnc #MDSsm
-
-
Mashup Score: 0
Monique Minnema, MD, PhD, University Medical Center Utrecht, Utrecht, Netherlands, gives a brief overview of bispecific antibodies emerging for the…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
We spoke with @MinnemaMonique at #EHA2022, who shared some interesting insights into various bispecific antibodies emerging for the treatment of multiple myeloma. Watch here: 👉https://t.co/myZzKmeoBo👈 @EHA_Hematology #MMsm #HemOnc #ImmunoOnc
-
-
Mashup Score: 3
Won Seog Kim, MD, PhD, Sungkyunkwan University School of Medicine, Seoul, South Korea, discusses the importance of plasma circulating tumor…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Learn more about the importance of circulating tumor DNA in patients with primary CNS lymphoma in our exclusive interview with Won Seog Kim (@SKKGSB): 🎥: https://t.co/4RBKve838R @EHA_Hematology #HemOnc #LymSM #EHA2022
-
-
Mashup Score: 1
John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci, Barts Cancer Institute, London, UK, discusses patient risk stratification in chronic lymphocytic…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
John Gribben (@bartsthelondon) discusses patient risk stratification in CLL and how prognostic factors influence treatment approaches. 🎥: https://t.co/lTpisM0YKF @EHA_Hematology #EHA2022 #HemOnc #CLLsm #LeuSM
-
-
Mashup Score: 0Advances in allogeneic CAR-T therapy in lymphoma - 2 year(s) ago
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses advances in allogeneic CAR-T therapy for the treatment of relapsed/refractory (R/R)…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Find out more about advances in allogeneic CAR-T therapy in lymphoma with leading expert @YiLinMDPhD in our exclusive interview: 👉https://t.co/lcAwKgoVDW👈 @EHA_Hematology #HemOnc #ImmunoOnc #CARTcell #tcellrx #LymSM #EHA2022
-
-
Mashup Score: 0Mechanisms of resistance to immunotherapy in NHL - 2 year(s) ago
Nilanjan Ghosh, MD, PhD, Atrium Health Levine Cancer Institute, Charlotte, NC, briefly discusses mechanisms of resistance to immunotherapy in non-Hodgkin…
Source: VJHemOncCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
At #EHA2022, we spoke with @NGhoshMD on mechanisms of resistance to immunotherapy in NHL. Watch his interview here: 🎥: https://t.co/JoeJ1ZfSNG @EHA_Hematology #HemOnc #LymSM #ImmunoOnc
-
-
Mashup Score: 4The Multiple Myeloma Daily - 2 year(s) ago
A selection of articles, blog posts, videos and photos recommended by Robert Z. Orlowski
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest The Multiple Myeloma Daily! https://t.co/y8LBo4h4Kt Thanks to @CyclingDoctor @MM_Hub @OnlineAMM #mmsm #eha2022
-
-
Mashup Score: 1High-risk cytogenetics in patients with NDMM treated with dara-KRd and tandem ASCT: Results of the IFM-2018-04 trial - 2 year(s) ago
In the IFM-2018-04 trial, the quadruplet of dara-KRd with tandem transplant was assessed in patients with NDMM eligible for transplant; Touzeau presented the results of this trial at the European Hematology Association (EHA) 2022 Congress, which we are pleased to summarize here.
Source: multiplemyelomahub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Catch up on the results of the IFM2018-04 study from #EHA2022 of transplant-eligible patients with newly diagnosed multiple #myeloma treated with tandem ASCT and quadruplet therapy 👇 #mmsm ⭐ https://t.co/2sVT6XvbLl ⭐ https://t.co/X6CF9wDxKI
-
-
Mashup Score: 0Does 10-day decitabine improve post-transplant outcomes in older patients compared with 3+7 chemo? - 2 year(s) ago
Ossenkoppele begins by introducing the study presented at the congress, outlining the study design and trial results. He then highlights the overall survival, and feasibility of this therapy as a bridge to allogeneic transplant. At the EHA 2022 Congress, Ossenkoppele received the Jean Bernard Lifetime Achievement Award, for his outstanding contribution to the advancement of hematology.
Source: aml-hub.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
💬 @GOssenkoppele begins by introducing the study presented #EHA2022, outlining the study design and trial results. He then highlights OS, and feasibility of this therapy as a bridge to allogeneic transplant 👉 https://t.co/mHqVJ5dkgu 👈 #AMLsm #leusm #leukemia https://t.co/HrxEZs2CBu
-
At #EHA2022 @MusaYilmazMD presented updated data on the combination of quizartinib, decitabine, and venetoclax in heavily pretreated FLT3-mutant #AML. Read our summary here: 👉 https://t.co/SmjPAIOcm0 👈 #AMLsm #leukemia #leusm